(Q39055724)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Saman Ahmad Nasrollahi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Mansour Nassiri Kashani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Alireza Firooz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Ashkan Hashemi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

22 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

Journal of Dermatological Treatment

3 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

476-483

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

The JAK-STAT pathway: impact on human disease and therapeutic intervention

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Therapeutic targeting of Janus kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

An update on topical therapies for mild-moderate psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Jakpot! New small molecules in autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Janus kinases: an ideal target for the treatment of autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Alopecia areata update: part II. Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Concepts of patients with alopecia areata about their disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Pharmacologic inhibition of JAK-STAT signaling promotes hair growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Efficacy of tofacitinib in treatment of alopecia universalis in two patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Vitiligo: a review of the published work

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

What patients with vitiligo believe about their condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Pathogenesis of dermatomyositis: role of cytokines and interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Remission of recalcitrant dermatomyositis treated with ruxolitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

IL-31: a new link between T cells and pruritus in atopic skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546634.2016.1277179

10.1080/09546634.2016.1277179

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28024126%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference